Oragenics Inc (OGEN)

$0.65 -0.04 (-6.09%)
Market Cap 2.94M
Revenue (ttm) 0.00
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 27,100
Avg Vol 417,278
Day's Range N/A - N/A
Shares Out 4.27M
Stochastic %K 53%
Beta 1.13
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplif...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Fax: 813 286 7900
Address:
1990 Main Street, Suite 750, Sarasota, United States
NMax
NMax Feb. 23 at 9:41 PM
$OGEN Just the simple word, ACQUISITION, and the biggest shill of them can't help himself. 🤣 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Feb. 23 at 9:18 PM
$OGEN .61/30 = .02, .02/60 = .0003. If you are holding since the Kim Murphy era your shares are now worth .0003 cents.
0 · Reply
NMax
NMax Feb. 23 at 8:53 PM
$OGEN Notice how fraudulent shills that have been dormant always get triggered at the mention of ACQUISITION 🤣 🤑🤑🤑
0 · Reply
profitingstocks
profitingstocks Feb. 23 at 6:03 PM
$OGEN can’t wait to see an updated share count, they must be blowing through that ATM offering
0 · Reply
RocketQueen
RocketQueen Feb. 23 at 4:13 PM
$OGEN less than 3k in volume?? Pathetic. Sold this garbage last April before the R/S, and now up over 400% on a new position. Meanwhile, OGEN dropped over 90%. I literally saved my account from cratering. Not ideal to lose anything, but at least back in the game.
0 · Reply
NMax
NMax Feb. 20 at 4:47 PM
$OGEN There is zero alternative to a buyout. Zero. I will continue to add. The fraudulent management and board of directors (who appear to be colluding to manipulate the price and sentiment) will be held accountable.
0 · Reply
kenpr
kenpr Feb. 20 at 4:13 PM
$OGEN shame on you CEO
1 · Reply
NMax
NMax Feb. 20 at 3:11 PM
$OGEN I know I'm right. So I'll just keep adding 🤑🤑🤑
1 · Reply
jlions
jlions Feb. 20 at 2:55 PM
$OGEN Chillwilly where are you? What now!
1 · Reply
RiskAdjustedAlpha
RiskAdjustedAlpha Feb. 20 at 1:20 PM
$OGEN Oragenics develops infectious disease therapies. Clinical progress drives valuation. Funding risk remains.
1 · Reply
Latest News on OGEN
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Feb 9, 2026, 8:30 AM EST - 14 days ago

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Feb 3, 2026, 8:30 AM EST - 20 days ago

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Oragenics Q3 2025 Shareholder Update

Nov 12, 2025, 8:30 AM EST - 3 months ago

Oragenics Q3 2025 Shareholder Update

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oct 21, 2025, 8:00 AM EDT - 4 months ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oct 7, 2025, 8:30 AM EDT - 4 months ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oragenics Q2 2025 Shareholder Update

Aug 11, 2025, 8:45 AM EDT - 7 months ago

Oragenics Q2 2025 Shareholder Update

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 16, 2025, 8:39 AM EDT - 7 months ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 8 months ago

Oragenics Completes Approximately $16.5 Million Offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 8 months ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 10 months ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 10 months ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 11 months ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 11 months ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 1 year ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 1 year ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 1 year ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 1 year ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 1 year ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 1 year ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 2 years ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 2 years ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 2 years ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 2 years ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 2 years ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 2 years ago

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Feb 12, 2024, 4:41 PM EST - 2 years ago

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Feb 7, 2024, 8:00 AM EST - 2 years ago

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Feb 5, 2024, 8:00 AM EST - 2 years ago

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Termination of At-The-Market Offering Program

Jan 23, 2024, 5:34 PM EST - 2 years ago

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Jan 2, 2024, 7:30 AM EST - 2 years ago

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Oragenics Issues Update to Shareholders

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Oragenics Issues Update to Shareholders

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oct 5, 2023, 6:30 AM EDT - 2 years ago

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

NMax
NMax Feb. 23 at 9:41 PM
$OGEN Just the simple word, ACQUISITION, and the biggest shill of them can't help himself. 🤣 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Feb. 23 at 9:18 PM
$OGEN .61/30 = .02, .02/60 = .0003. If you are holding since the Kim Murphy era your shares are now worth .0003 cents.
0 · Reply
NMax
NMax Feb. 23 at 8:53 PM
$OGEN Notice how fraudulent shills that have been dormant always get triggered at the mention of ACQUISITION 🤣 🤑🤑🤑
0 · Reply
profitingstocks
profitingstocks Feb. 23 at 6:03 PM
$OGEN can’t wait to see an updated share count, they must be blowing through that ATM offering
0 · Reply
RocketQueen
RocketQueen Feb. 23 at 4:13 PM
$OGEN less than 3k in volume?? Pathetic. Sold this garbage last April before the R/S, and now up over 400% on a new position. Meanwhile, OGEN dropped over 90%. I literally saved my account from cratering. Not ideal to lose anything, but at least back in the game.
0 · Reply
NMax
NMax Feb. 20 at 4:47 PM
$OGEN There is zero alternative to a buyout. Zero. I will continue to add. The fraudulent management and board of directors (who appear to be colluding to manipulate the price and sentiment) will be held accountable.
0 · Reply
kenpr
kenpr Feb. 20 at 4:13 PM
$OGEN shame on you CEO
1 · Reply
NMax
NMax Feb. 20 at 3:11 PM
$OGEN I know I'm right. So I'll just keep adding 🤑🤑🤑
1 · Reply
jlions
jlions Feb. 20 at 2:55 PM
$OGEN Chillwilly where are you? What now!
1 · Reply
RiskAdjustedAlpha
RiskAdjustedAlpha Feb. 20 at 1:20 PM
$OGEN Oragenics develops infectious disease therapies. Clinical progress drives valuation. Funding risk remains.
1 · Reply
SXCross
SXCross Feb. 18 at 3:59 PM
$OGEN new investor: Xtx Topco Ltd 12/31/2025 33,747
0 · Reply
NMax
NMax Feb. 18 at 1:33 AM
$OGEN continuing to add 😎 🤑🤑🤑
1 · Reply
RocketQueen
RocketQueen Feb. 17 at 7:25 PM
$OGEN .63/30 = .02, .02/60 = .0003 --- and they are headed for another R/S soon.
0 · Reply
trendricky
trendricky Feb. 17 at 8:27 AM
$OGEN Pre-revenue biotech; CNS focus
0 · Reply
TaintMcBalls
TaintMcBalls Feb. 17 at 3:25 AM
This is the ticket. Throw it on the watchlist $OGEN $ROKU $R $V
0 · Reply
SXCross
SXCross Feb. 16 at 4:13 PM
$OGEN Drw Securities has increased its inventory, Llc 12/31/2025 up to 112,709 ( before 50,900) + 82.35%
0 · Reply
RocketQueen
RocketQueen Feb. 13 at 11:52 PM
$OGEN no employees, no labs, no office, no viable products and no future.
1 · Reply
SXCross
SXCross Feb. 12 at 4:54 PM
$OGEN Short-Interest 524.157
1 · Reply
RocketQueen
RocketQueen Feb. 12 at 3:13 PM
$OGEN garbage, surprised this has not yet dipped below twenty cents. It could take forever for Australia to take a look at the nasal scam.
0 · Reply
Dh15708
Dh15708 Feb. 11 at 9:21 PM
$OGEN Here's a company thats trying to get into concussion treatments but with a different approach. https://www.startengine.com/offering/oxeia-biopharma
0 · Reply
RocketQueen
RocketQueen Feb. 11 at 5:23 PM
$OGEN it could take the Australian hospital system forever to consider the clinical trials for the nasal scam. Meanwhile, the stock price will continue to fall with dilution, salary payments and other factors.
0 · Reply
kenpr
kenpr Feb. 11 at 10:12 AM
$OGEN provide evidence of results delivered to your investors., otherwise are all empty promises
0 · Reply